Crossmark Global Holdings, Inc. Galapagos Nv Transaction History

Crossmark Global Holdings, Inc.

$5.5 Billion
Q1 2025

A detailed history of Crossmark Global Holdings, Inc. transactions in Galapagos Nv stock. As of the latest transaction made, Crossmark Global Holdings, Inc. holds 49,332 shares of GLPG stock, worth $1.42 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

49,332

Previous 49,163 0.34%

Holding current value

$1.42 Million

Previous $1.35 Million 8.36%

% of portfolio

0.02%

Previous 0.02%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 Apr 29, 2025	BUY	$22.69 - $28.79 $3,834 - $4,865	169 Added 0.34%	49,332 $1.24 Million
Q4 2024 Jan 16, 2025	BUY	$25.22 - $31.05 $297,015 - $365,675	11,777 Added 31.5%	49,163 $1.35 Million
Q3 2024 Nov 04, 2024	BUY	$24.2 - $30.67 $904,741 - $1.15 Million	37,386 New	37,386 $1.08 Million
Q2 2021 Jul 21, 2021	SELL	$68.86 - $83.34 $377,077 - $456,369	-5,476 Closed	0 $0
Q1 2021 Apr 15, 2021	SELL	$76.15 - $111.94 $1,827 - $2,686	-24 Reduced 0.44%	5,476 $422,000
Q4 2020 Jan 14, 2021	BUY	$96.85 - $148.25 $51,330 - $78,572	530 Added 10.66%	5,500 $544,000
Q3 2020 Oct 08, 2020	BUY	$122.47 - $213.56 $35,516 - $61,932	290 Added 6.2%	4,970 $705,000
Q2 2020 Aug 14, 2020	BUY	$185.52 - $231.25 $54,542 - $67,987	294 Added 6.7%	4,680 $923,000
Q1 2020 Apr 28, 2020	BUY	$143.0 - $274.03 $67,210 - $128,794	470 Added 12.0%	4,386 $859,000
Q4 2019 Feb 06, 2020	SELL	$146.12 - $215.82 $29,808 - $44,027	-204 Reduced 4.95%	3,916 $810,000
Q3 2019 Oct 09, 2019	BUY	$130.44 - $187.64 $537,412 - $773,076	4,120 New	4,120 $629,000

Others Institutions Holding GLPG

# of Institutions

Shares Held

13.4M

Call Options Held

216K

Put Options Held

313K

View Full List

About GALAPAGOS NV

Ticker GLPG
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,835,500
Market Cap $1.9B
Description
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative coliti...

More about GLPG

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Crossmark Global Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Crossmark Global Holdings, Inc. with notifications on news.

Account

Crossmark Global Holdings, Inc. Galapagos Nv Transaction History